Physician profile
Daniel Barnes Webb
NPI 1033310552
$5,784.63
in general payments reported to CMS, 2019-2025
20 companies · $150 in 2025
The $150 reported for 2025 was less than what a typical Neurological Surgery provider received nationally (typical 2025 total: $604).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $291 · 2020: $193 · 2022: $984 · 2023: $1,409 · 2024: $2,758 · 2025: $150.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $3,766 · Food and Beverage: $550.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $3,766.36 |
| Food and Beverage | $550.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Synthes Gmbh | $3,180.43 | 2023-2024 | |
| Centinel Spine, LLC | $936.93 | 2022 | |
| Medtronic, INC. | $738.23 | 2024 | Space-D System 5.5/6.0 Voyager Instrument Set, Catalyft Pl Expandable Interbody System, Mazor X System |
| Depuy Synthes Sales INC. | $202.87 | 2020-2025 | Synfix Evolution, Viper |
| Zimvie INC. | $144.90 | 2024 | |
| Medtronic USA, INC. | $93.00 | 2020 | |
| Abbvie INC. | $82.00 | 2019-2024 | Ubrelvy |
| Amgen INC. | $70.11 | 2019-2020 | |
| Supernus Pharmaceuticals, INC. | $61.74 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $57.33 | 2020-2022 | |
| Csl Behring | $46.31 | 2019 | |
| Acorda Therapeutics, INC | $38.19 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $23.18 | 2023 | Austedo |
| Alexion Pharmaceuticals, INC. | $21.94 | 2019 | |
| Ucb, INC. | $18.62 | 2019 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aquestive Therapeutics, INC. | $16.88 | 2019 | |
| Upsher-Smith Laboratories LLC | $16.23 | 2022 | |
| Novartis Pharmaceuticals Corporation | $12.30 | 2019 | |
| Neurocrine Biosciences, INC. | $12.12 | 2020 | |
| Portola Pharmaceuticals, LLC | $11.32 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Webb listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.